PharmaCE- Continuing Education

Eszopiclone for Insomnia

Sarah T Melton, Jill M Wood, and Cynthia K Kirkwood

Email to a FriendEmail to a Friend       Add to Cart  Add to Cart         Continue Shopping

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy data, and adverse effects of eszopiclone in the treatment of transient and chronic insomnia in adult and geriatric patients.

DATA SOURCES:
A MEDLINE literature search (1966-May 2005) was conducted to retrieve articles and abstracts involving eszopiclone. The manufacturer of the drug provided a general summary of clinical data and abstracts of unpublished Phase III clinical trials.

STUDY SELECTION AND DATA EXTRACTION:
All articles identified from the data sources were reviewed, and information deemed relevant was included for this review.

DATA SYNTHESIS:
Food and Drug Administration approval of eszopiclone was based on 6 double-blind, placebo-controlled trials. Five trials published in abstract or study form were reviewed. The sixth trial was not available for evaluation. An open-label continuation trial was also reviewed. All studies showed statistically significant improvements in sleep parameters in adult and elderly patients treated for insomnia with eszopiclone.

CONCLUSIONS:
The results of the 5 available double-blind, placebo-controlled studies (and 1 open-label, 6-month extension) showed that eszopiclone was safe and effective in the treatment of transient and chronic insomnia in adult and geriatric patients. Tolerance with long-term exposure (6 mo) and rebound insomnia were not observed. The results of the 6-month, open-label extension trial demonstrated that improvements in sleep parameters were sustained. Future studies comparing eszopiclone with other non benzodiazepine sedative-hypnotics (eg, zolpidem, zaleplon) are needed with cost data to clearly define the role of eszopiclone in the pharmacotherapy of chronic insomnia.
Key Words: eszopiclone, hypnotics, sedative-hypnotics, insomnia

Published Online, August 30, 2005. www.theannals.com, DOI 10.1345/aph.1G179

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER:
407-000-05-027-H01


PharmaCETM
is a service of HARVEY WHITNEY BOOKS COMPANY
8044 Montgomery Road, Suite 415, Cincinnati, OH 45236-2919
P.O. Box 42696, Cincinnati, OH 45242-0696 USA
Toll Free: 877/742-7631
Tel. 513/793-3555, FAX 513/793-3600
Office Hours: Monday - Friday 9-5 E.S.T.
Contact Us
All Rights Reserved. Copyright © 1998-